8-K: Philip Morris International Updates 2026 EPS Forecast

Philip Morris International updates its 2026 full-year reported diluted EPS forecast to $7.18-$7.33, reflecting currency impacts and a non-cash impairment charge.

Summary

• Philip Morris International (PMI) announced an update to its 2026 full-year reported diluted Earnings Per Share (EPS) forecast, now projected to be between $7.18 and $7.33.
• This revised forecast accounts for currency fluctuations and a non-cash impairment charge related to its investment in RBH (Canada).
• Excluding a total adjustment of $1.13 per share for the full year, the adjusted diluted EPS forecast is $8.31 to $8.46, representing a projected increase of 10.2% to 12.2% compared to 2025.
• Excluding a favorable currency impact of $0.20 per share, the growth is projected at 7.5% to 9.5%.
• The non-cash impairment charge is approximately $500 million, or 33 cents per diluted EPS, expected in the second quarter of 2026, due to updated financial projections for RBH.
• PMI's Group CEO, Jacek Olczak, discussed the company's strong full-year performance expectations, driven by its international multi-category smoke-free business, particularly IQOS.
• Developments in the heat-not-burn category, including Japan's market post-excise tax increase, and the U.S. ZYN portfolio expansion with ZYN ULTRA were also highlighted.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive update. While the reported EPS forecast is lowered due to specific charges, the underlying adjusted EPS growth projections remain robust, and strategic initiatives like ZYN ULTRA expansion are positive.

Positives

• Continued expectation of strong full-year performance driven by broad-based momentum in the international multi-category smoke-free business, led by IQOS.
• U.S. ZYN portfolio expansion, including the launch of ZYN ULTRA, aiming to optimize ZYN's price premium.
• Projected adjusted diluted EPS growth of 10.2% to 12.2% (or 7.5% to 9.5% excluding currency) for 2026 compared to 2025.
• IQOS maintaining a strong category share in Japan despite recent excise tax increases.
• PMI's long-term ambition to expand into wellness areas, leveraging its life sciences expertise.

Negatives

• A non-cash impairment charge of approximately $500 million (33 cents per diluted EPS) is expected in Q2 2026 related to the investment in RBH (Canada).
• The reported diluted EPS forecast is revised downwards to $7.18-$7.33 due to currency and the RBH impairment.
• Unfavorable currency impact of 3 cents is now estimated for Q2 2026 adjusted diluted EPS.
• The company acknowledges risks associated with currency exchange rates, devaluations, and limitations on repatriating funds.

Risks

• Marketing and regulatory restrictions that could reduce competitiveness, disrupt smoke-free product commercialization, or ban products.
• Excise tax increases and discriminatory tax structures.
• Health concerns related to tobacco and nicotine products.
• Litigation related to tobacco/nicotine products and intellectual property.
• Intense competition and inability to anticipate changes in adult consumer preferences.
• Adverse effects of global and country-specific economic, regulatory, and political developments, natural disasters, and conflicts.
• Geopolitical instability affecting international trade and the impact of Russia's invasion of Ukraine.
• Changes in adult smoker behavior, continued decline of tax-paid cigarettes, and lost revenues from counterfeiting and contraband.

Future Outlook

PMI maintains expectations for a strong full-year performance in 2026, driven by its international multi-category smoke-free business. The company has updated its reported diluted EPS forecast to a range of $7.18 to $7.33, primarily due to currency impacts and a non-cash impairment charge. Excluding these items, the adjusted diluted EPS forecast of $8.31 to $8.46 represents projected growth of 10.2% to 12.2% over 2025. Further extensions of the ZYN portfolio are planned for the remainder of the year.

Management Comments

• PMI's continued expectation of a strong full-year performance, notably driven by the broad-based momentum of our international multicategory smoke-free business, led by IQOS.
• Recent heat-not-burn category developments broadly in-line with our expectations, most notably in Japan following the April 1, 2026 excise tax increase, with April offtake impacted by consumer pantry de-loading and IQOS maintaining a strong category share.
• U.S. ZYN portfolio expansion, including the launch of ZYN ULTRA this month in 9mg and 11mg moist variants. Available in a 20-pouch can format, ZYN ULTRA will be positioned at a lower list price-per-pouch than the flagship dry ZYN portfolio (15-pouch format), marking an important step in optimizing ZYNs price premium.

Industry Context

StockSavvy.ai notes that PMI's update reflects ongoing strategic shifts within the consumer goods sector towards reduced-risk products. The company's focus on its smoke-free portfolio, including IQOS and ZYN, aligns with broader industry trends of innovation and diversification away from traditional tobacco products, while also navigating evolving regulatory and tax landscapes.

Legal Proceedings

• Income tax impact associated with Swedish Match AB financing is noted as an adjustment item.

Stakeholder Impact

• Shareholders: The updated EPS forecast may influence short-term investor sentiment, though underlying growth projections are positive.
• Consumers: Continued development and expansion of smoke-free products like IQOS and ZYN offer evolving options.
• Employees: The company's strategic focus on smoke-free products and potential expansion into wellness areas could impact future roles and opportunities.

Next Steps

• Continue broad-based momentum of the international multi-category smoke-free business, led by IQOS.
• Monitor heat-not-burn category developments, particularly in Japan post-excise tax increase.
• Expand U.S. ZYN portfolio with further extensions planned for the remainder of the year.
• Record a non-cash impairment charge of approximately $500 million in the second quarter of 2026.
• Continue to develop, scientifically substantiate, and commercialize innovative smoke-free products.

Key Dates

Recommendation

The filing presents a mixed picture. While the adjusted EPS growth forecast remains positive, the reduction in the reported EPS forecast due to a significant non-cash impairment charge introduces a degree of caution. The company's strategic direction in smoke-free products is strong, but the impairment and currency headwinds warrant a 'hold' stance until further clarity on the impact of these factors emerges.

Keywords

Philip Morris International, PMI, EPS forecast, smoke-free products, IQOS, ZYN, RBH impairment, dbAccess Global Consumer Conference